Home » Stocks » CAPR

Capricor Therapeutics, Inc. (CAPR)

Stock Price: $5.34 USD 0.28 (5.53%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $6.15 +0.81 (15.17%) Mar 5, 7:59 PM
Market Cap 109.19M
Revenue (ttm) 474,520
Net Income (ttm) -10.95M
Shares Out 19.80M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $5.34
Previous Close $5.06
Change ($) 0.28
Change (%) 5.53%
Day's Open 5.10
Day's Range 4.62 - 5.39
Day's Volume 517,203
52-Week Range 0.88 - 12.32

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

-Technology Licensed from Johns Hopkins University-

GlobeNewsWire - 1 month ago

-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs-

GlobeNewsWire - 1 month ago

—Capricor to leverage Lonza's expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply—

GlobeNewsWire - 2 months ago

Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19 Trial Assessing Ability of Capricor's Cardiac Cell Therapy, C...

GlobeNewsWire - 3 months ago

- Data Expected Second Quarter 2021 -

Seeking Alpha - 3 months ago

Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- - Novel Vaccine Induce d Long-Lasting Immunity to Multiple SARS-CoV-2 Protei...

GlobeNewsWire - 3 months ago

Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins

GlobeNewsWire - 4 months ago

Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET

GlobeNewsWire - 5 months ago

--Final 12-Month Results from Phase II Trial to be Presented on October 1-- LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage bi...

GlobeNewsWire - 5 months ago

LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell ...

Benzinga - 6 months ago

Capricor Therapeutics (NASDAQ: CAPR) shares are trading higher on Tuesday after the company announced the U.S.

GlobeNewsWire - 6 months ago

– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 –

Seeking Alpha - 6 months ago

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 7 months ago

Exosome Platform for COVID-19 -Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies- -Preclinical Data Shows Positive Antibody Response-

GlobeNewsWire - 7 months ago

Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET

Zacks Investment Research - 7 months ago

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 9 months ago

Capricor Therapeutics Inc. (CAPR) CEO Linda Marban on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Capricor (CAPR) delivered earnings and revenue surprises of 16.67% and -11.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 9 months ago

Duchenne Muscular Dystrophy Program -Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of Upper Lim...

Benzinga - 10 months ago

Capricor Therapeutics Inc.’s (NASDAQ: CAPR) shares soared after data that pointed to a 100 percent survival rate in critical COVID-19 patients treated with new CAP-1002 cardiac cell therapy wa...

GlobeNewsWire - 10 months ago

U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients

GlobeNewsWire - 11 months ago

­LOS ANGELES, April 03, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutic...

Zacks Investment Research - 11 months ago

Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.

Other stocks mentioned: MASI, MRNA, QGEN
Seeking Alpha - 11 months ago

Capricor Therapeutics' (CAPR) CEO Linda Marban on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

Company Appoints Stephen Gould, Ph.D. as Executive Consultant for its Exosomes Program Company Appoints Stephen Gould, Ph.D. as Executive Consultant for its Exosomes Program

Zacks Investment Research - 1 year ago

Is (CAPR) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for February 3rd

Other stocks mentioned: CLS, SNE, TROW
Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for January 28th

Other stocks mentioned: PERI, SNE, STM
GlobeNewsWire - 1 year ago

LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological ther...

GlobeNewsWire - 1 year ago

LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological ther...

Seeking Alpha - 1 year ago

Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Capricor (CAPR) delivered earnings and revenue surprises of 38.57% and -35.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

Call Scheduled for Thursday, October 24th at 10:30am Eastern Time

GlobeNewsWire - 1 year ago

--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies-- --Company to Host Conference Call Today at 5:30 AM PT / 8:30...

Market Watch - 1 year ago

Capricor Therapeutics shares CAPR, -0.32% rose 3.6% in premarket trade Tuesday, after the clinical-stage biotech said the U.s.

GlobeNewsWire - 1 year ago

Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies Company Exploring Potential for Accelerated Approval under RMAT Des...

GlobeNewsWire - 1 year ago

Dr. Craig McDonald to Provide Update in Late Breaking Oral Presentation Dr. Craig McDonald to Provide Update in Late Breaking Oral Presentation

GlobeNewsWire - 1 year ago

LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeu...

Seeking Alpha - 1 year ago

Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Capricor (CAPR) delivered earnings and revenue surprises of 26.25% and 86.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Capricor announced positive interim results from its phase 2 HOPE-2 study using CAP-1002 to treat patients with Duchenne muscular dystrophy.

InvestorPlace - 1 year ago

Capricor Therapeutics news about the results from a recent clinical trial for its CAP-1002 therapy has CAPR stock soaring Monday. The post Capricor Therapeutics News: Why CAPR Stock Is Skyrock...

24/7 Wall Street - 1 year ago

Capricor Therapeutics Inc. shares more than doubled on Monday after the firm announced interim analysis for its Duchenne muscular dystrophy (DMD) midstage trial.

Market Watch - 1 year ago

Shares of Capricor Therapeutics Inc. nearly doubled (up 93%) in very active premarket trading Monday, after the biotechnology company announced upbeat results from a trial for its treatment (C...

Seeking Alpha - 1 year ago

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q4 2018 Results - Earnings Call Transcript

About CAPR

Capricor Therapeutics, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatme... [Read more...]

Industry
Biotechnology
Founded
2005
CEO
Linda Marban
Employees
16
Stock Exchange
NASDAQ
Ticker Symbol
CAPR
Full Company Profile

Financial Performance

In 2019, CAPR's revenue was $1.01 million, a decrease of -39.87% compared to the previous year's $1.67 million. Losses were -$7.64 million, -49.70% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CAPR stock is "Buy" and the 12-month stock price forecast is 12.00.

Price Target
$12.00
Analyst Consensus: Buy